Kymera Therapeutics (NASDAQ:KYMR) CFO Bruce Jacobs Sells 77,109 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce Jacobs sold 77,109 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the transaction, the chief financial officer directly owned 244,883 shares of the company’s stock, valued at approximately $28,151,749.68. The trade was a 23.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Kymera Therapeutics Trading Down 0.6%

KYMR opened at $113.51 on Friday. The company’s 50 day moving average is $86.87 and its 200-day moving average is $82.91. Kymera Therapeutics, Inc. has a 1-year low of $36.65 and a 1-year high of $130.05. The company has a market cap of $9.34 billion, a P/E ratio of -31.80 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm’s revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.82) EPS. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KYMR. Smartleaf Asset Management LLC lifted its holdings in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares during the period. Larson Financial Group LLC boosted its holdings in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics in the fourth quarter valued at approximately $63,000. Osaic Holdings Inc. increased its position in Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares during the period. Finally, PNC Financial Services Group Inc. increased its position in Kymera Therapeutics by 56.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock valued at $107,000 after purchasing an additional 463 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on KYMR shares. Canaccord Genuity Group raised their price objective on Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a report on Friday, June 26th. Jefferies Financial Group started coverage on Kymera Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $110.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Bank of America lifted their price target on Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Truist Financial upped their price objective on Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $121.41.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.